Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 18/20 | 0.60 |
| ▸ | ESR1 | P03372 | 14/20 | 0.60 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422946 | 0.91 | ESR2 (0.73) | ESR2ESR1 | |
| SCHEMBL4857333 | 0.90 | ESR2 (0.62) | ESR2ESR1 | |
| SCHEMBL4854661 | 0.89 | ESR2 (0.55) | ESR2ESR1 | |
| SCHEMBL4860203 | 0.84 | ESR2 (0.61) | ESR2ESR1 | |
| SCHEMBL4858848 | 0.82 | ESR2 (0.80) | ESR2ESR1 | |
| SCHEMBL4852297 | 0.79 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL6151438 | 0.79 | ESR2 (0.58) | ESR2ESR1 | |
| SCHEMBL2418445 | 0.74 | ESR2 (0.72) | ESR2ESR1 | |
| SCHEMBL21553806 | 0.74 | SMN1; SMN2 (0.45) | ESR2ESR1METAP1DYRK1A | |
| SCHEMBL2417960 | 0.74 | ESR2 (0.73) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1551820-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026887-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885METAP1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.